Table 2.

Data from real-life risankizumab (long-term follow-up) studies.

Reference	Follow-Up (Weeks)	Number of Patients	PASI 90	PASI 100
Gkalpakiotis, S. [10]	52	154	82.4%	67.6%
Borroni, R.G. [11]	40	66	85.7%	62.3%
Hansel, K. [12]	52	57	85.5%	60%
Mastorino, L. [13]	52	166	82%	73%
Megna, M. [14]	52	39	84.6%	64.1%
Caldarola, G. [9]	52	63	95.24%	90.5%
Metha, M. [15]	44	70		46% (IGA = 0)
Gargiulo, L. [16]	52	131	61.1%	78.6%